Pharming N : Presentation AGM 2024

Pharming Group N.V.

2024 Annual General

Meeting of Shareholders

May 21, 2024

NASDAQ: PHAR | EURONEXT Amsterdam: PHARM

DISCUSSION ITEM

AGENDA ITEMS: 1/8

1. Opening and announcements

(discussion item)

Leadership: Board of Directors

Sijmen de Vries, MD, MBA

Executive Director

& Chief Executive Officer

Deborah Jorn, MBA

Vice-Chair of the Board of Directors , Member of the Remuneration Committee & Member of the Audit Committee

Mark Pykett, VMD, PhD

Non-Executive Director, Member of the

Remuneration Committee & the Transaction

Committee

Jabine van der Meijs

Non-Executive Director, Chairperson of the

Corporate Governance Committee, Member of the

Audit Committee & Remuneration Committee

Richard Peters, MD, PhD

Chairman of the Board of Directors, Member of the Corporate Governance Committee & the Transaction Committee

Barbara Yanni

Non-Executive Director, Chairperson of the

Transaction Committee, Member of the Audit

Committee & the Corporate Governance Committee

Leonard Kruimer

Non-ExecutiveDirector, Chairperson of the Audit Committee & Member of the Transaction Committee

Steven Baert

Non-Executive Director, Chairperson of the

Remuneration Committee & Member of

the Corporate Governance Committee

3

Leadership: Executive Committee

Sijmen de Vries, MD MBA
Executive Director &	CEO
Chief Executive Officer

Anurag Relan MD

Chief Medical Officer

CMO

Stephen Toor

Chief Commercial Officer

CCO

Dr. Alexander

Breidenbach, MBA	CBO
Chief Business Officer

Jeroen Wakkerman

Chief Finance Officer

CFO

Mireille Sanders MSc

Chief Operations Officer

COO

Ruud van Outersterp
Chief Ethics &	CECO
Compliance Officer

4

Agenda

1. Opening and announcements
2. Annual Report 2023 (voting and discussion items)
3. 1. Explanation of the business, the operations and the results for the year ending on December 31, 2023 (discussion item)
   2. Remuneration report for 2023 (advisory voting item)
   3. Corporate Governance (discussion item)
   4. Explanation of the dividend policy (discussion item)
   5. Proposal to adopt the financial statements for 2023 (voting item)
   6. Proposal to discharge the members of the Board of Directors (voting item).
4. Adoption Updated Remuneration Policy for the Board of Directors (voting item)
5. Reappointment Non-Executive Directors (2 separate voting items)
6. 1. Proposal to reappoint Ms. Barbara Yanni, upon binding recommendation of the Board of Directors, as Non-Executive Director, for a period of four years.
   2. Proposal to reappoint Mr. Mark Pykett, upon binding recommendation of the Board of Directors, as Non-Executive Director, for a period of four years.
7. Designation of the Board of Directors as the Company's body, authorized to: (i) issue shares, (ii) grant option rights and (iii) restrict or exclude pre-emptive rights (voting items):
   General authorization for generic corporate purposes, including (i) share issuances to the Board of Directors in accordance with the remuneration policy and the incentive plans for the CEO as approved by our shareholders, and (ii) issuances of shares and/or stock options to staff members under the applicable staff equity incentive plans, for a period of eighteen months, starting on May 21, 2024, up to 10% of the issued share capital.
8. Authorization of the Board of Directors to repurchase shares in the Company (voting item)
   Proposal to authorize the Board of Directors for a period of eighteen months starting on May 21, 2024, as the Company's body authorized to resolve to repurchase not more than 10% of the issued capital through the stock exchange or otherwise.
9. Any other business (discussion item)
10. Closing

5

VOTING &

DISCUSSION ITEMS

AGENDA ITEMS: 2/8

2. Annual Report 2023

(voting and discussion items)

1. Explanation of the business, the operations and the results for the year ending on December 31, 2023 (discussion item)
2. Remuneration report for 2023 (advisory voting item)
3. Corporate Governance (discussion item)
4. Explanation of the dividend policy (discussion item)
5. Proposal to adopt the financial statements for 2023 (voting item)
6. Proposal to discharge the members of the Board of Directors (voting item).

VOTING &

DISCUSSION ITEMS

AGENDA ITEMS: 2/8

2. Annual Report 2023

(voting and discussion items)

1. Explanation of the business, the operations and the results for the year ending on December 31, 2023 (discussion item)
2. Remuneration report for 2023 (advisory voting item)
3. Corporate Governance (discussion item)
4. Explanation of the dividend policy (discussion item)
5. Proposal to adopt the financial statements for 2023 (voting item)
6. Proposal to discharge the members of the Board of Directors (voting item).

CEO

Sijmen de Vries, MD

Chief Executive Officer

Introduction

Forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", ''anticipate'', ''believe'', ''could'', ''estimate'', ''expect'', ''goals'', ''intend'', ''may'', "milestones", ''objectives'', ''outlook'', ''plan'', ''probably'', ''project'', ''risks'', "schedule", ''seek'', ''should'', ''target'', ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward- looking statements. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Pharming as of the date of this presentation. Pharming does not undertake any obligation to publicly update or revise any forward- looking statement as a result of new information, future events or other information.

9

Building a leading global rare disease biopharma company

Market RUCONEST®

for acute HAE attacks in key

markets - U.S. focus

Positive cash flow from RUCONEST® revenue funds Joenja® (leniolisib) launches & pipeline development

FY23 revenue US$227.1M

1Q24 revenue US$46.0M (+8%)

Increase in patients and prescribers driving growth

Patients reliant on RUCONEST® despite increased therapy options

Global approvals and commercialization of Joenja® (leniolisib) for APDS

Successful commercialization of Joenja® (leniolisib) - first and only FDA approved treatment for APDS - U.S. launch April 2023

Revenue FY23 US$18.2M

1Q24 US$9.6M (+21% vs. 4Q23) Strong focus on patient finding

Israel approval (April 2024)

Regulatory reviews ongoing in EUR, U.K., CAN, AUS Pediatric and Japan clinical trials

Ongoing pipeline development

and management of rare

disease assets

Advance internal projects and rare disease in-licensing and acquisition strategy

Leniolisib development for PIDs with immune dysregulation beyond APDS - preparing Ph2

BD focus on clinical programs in immunology, hematology, respiratory and gastroenterology

OTL- 105 discontinued

2024 Total Revenue Guidance - $280 - $295M (14 - 20% growth)	10
Driven by Joenja®